TrialFrontiers in immunology2022

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19.

Valentina Mazzotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.